Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST



Status:Recruiting
Conditions:High Blood Pressure (Hypertension)
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - 75
Updated:3/30/2019
Start Date:October 4, 2016
End Date:June 2020

Use our guide to learn which trials are right for you!

A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension

This study assesses the safety and efficacy of bardoxolone methyl relative to placebo in
patients with connective tissue disease-associated pulmonary arterial hypertension to
determine the recommended dose range and evaluate the change from baseline in 6-minute walk
distance (6MWD) following 24 weeks of study participation.

This double-blind, randomized, placebo-controlled trial will study the safety, tolerability,
and efficacy of bardoxolone methyl in qualified patients with WHO Group I CTD-PAH.

Qualified patients will be randomized 1:1 to either bardoxolone methyl or placebo to be
administered once daily for 24 weeks. Patients randomized to placebo will remain on placebo
throughout the study. Patients randomized to bardoxolone methyl will start at 5 mg and will
dose-escalate to 10 mg at Week 4 unless contraindicated clinically. Dose de-escalation is
permitted during the study if indicated clinically.

All patients in the study will follow the same visit and assessment schedule. Following
randomization, patients will be scheduled to be assessed in person during treatment at Weeks
1, 2, 4, 6, 8, 16, and 24 and by telephone contact on Days 3, 10, 21, 31, 38, 84, and 140.
Patients will also be scheduled to be assessed at an in person follow up visit at Week 28,
four weeks after the end of treatment.

Inclusion Criteria:

- BMI > 18.5 kg/m2;

- Symptomatic pulmonary hypertension WHO/NYHA FC class II and III;

- WHO Group I PAH associated with connective tissue disease;

- Had a diagnostic right heart catheterization performed and documented within 36 months
prior to Day 1 that confirmed a diagnosis of PAH according to all the following
criteria:

- Mean pulmonary artery pressure ≥ 25 mm Hg (at rest);

- Pulmonary capillary wedge pressure (PCWP) ≤ 15 mm Hg;

- Pulmonary vascular resistance > 240 dyn.sec/cm5 or > 3 mm Hg/liter (L)/minute;

- Has BNP level ≤ 400 pg/mL;

- Had an average 6MWD ≥ 150 meters on two consecutive tests performed on different days
prior to randomization, with both tests measuring within 15% of one another;

- Has been receiving no more than two (2) approved disease-specific PAH therapies. PAH
therapy must have been at a stable dose for at least 90 days prior to Day 1. No
additions or changes should be made to PAH therapies and doses should remain stable
for the duration of the study;

- Has maintained a stable dose for 30 days prior to Day 1 if receiving any of the
following therapies that may affect PAH: vasodilators (including calcium channel
blockers), digoxin, L-arginine supplementation, or oxygen supplementation. No
additions or changes should be made to therapies and doses should remain stable for
the duration of the study;

- If receiving treatment for CTD with prednisone or any other drugs, doses must remain
stable for at least 30 days prior to Day 1 and for the duration of the study Had
pulmonary function tests (PFTs) within 90 days prior to Day 1 with total lung capacity
≥ 65% (predicted);

- Had a ventilation-perfusion (V/Q) lung scan, spiral/helical/electron beam computed
tomography (CT), or pulmonary angiogram prior to Day 1 that shows no evidence of
thromboembolic disease (i.e., should note normal or low probability for pulmonary
embolism). If V/Q scan was abnormal (i.e., results other than normal or low
probability), then a confirmatory CT or selective pulmonary angiography must exclude
chronic thromboembolic pulmonary hypertension;

- Has adequate kidney function defined as an estimated glomerular filtration rate (eGFR)
≥ 45 mL/min/1.73 m2 as measured by the central lab;

- Willing and able to comply with scheduled visits, treatment plan, laboratory tests,
and other study procedures;

- Evidence of a personally signed and dated informed consent document indicating that
the patient (or a legally acceptable representative) has been informed of all
pertinent aspects of the study prior to initiation of any patient-mandated procedures

Exclusion Criteria:

- Participation in other investigational clinical studies involving interventional
products being tested or used in a way different from the approved form or when used
for an unapproved indication within 30 days prior to Day 1;

- Initiation of an exercise program for cardio-pulmonary rehabilitation within 90 days
prior to Day 1 or planned initiation during the study;

- Stopped receiving any PAH chronic therapy within 60 days prior to Day 1;

- Received a dose of prednisone > 20 mg/day (or equivalent dose if other corticosteroid)
within 30 days prior to Day 1;

- Received intravenous (iv) or subcutaneous (sc) prostacyclin/prostacyclin analogues
within 90 days prior to Day 1;

- Received intravenous inotropes within 30 days prior to Day 1;

- Has uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure
(BP) > 160 mm Hg or sitting diastolic BP > 100 mm Hg during Screening after a period
of rest;

- Has systolic BP < 90 mm Hg during Screening after a period of rest;

- Has a history of clinically significant left-sided heart disease and/or clinically
significant cardiac disease, including but not limited to any of the following:

- Congenital or acquired valvular disease if clinically significant apart from
tricuspid valvular insufficiency due to pulmonary hypertension;

- Pericardial constriction;

- Restrictive or congestive cardiomyopathy;

- Left ventricular ejection fraction < 40% per echocardiogram (ECHO) within 90 days
of Day 1;

- Symptomatic coronary artery disease within the last 3 years;

- Acutely decompensated heart failure within 30 days prior to Day 1, per investigator
assessment;

- Has more than two of the following clinical risk factors for left ventricular
diastolic dysfunction:

- Age > 65 years;

- BMI ≥ 30 kg/m2;

- History of systemic hypertension;

- History of type 2 diabetes;

- History of atrial fibrillation;

- History of atrial septostomy within 180 days prior to Day 1;

- History of uncontrolled obstructive sleep apnea;

- Has a history of portal hypertension or chronic liver disease, including hepatitis B
and/or hepatitis C (with evidence of recent infection and/or active virus replication)
defined as mild to severe hepatic impairment (Child-Pugh Class A-C);

- Serum aminotransferase (ALT or AST) levels > 1.5X the upper limit of normal (ULN) at
Screening;

- Hemoglobin (Hgb) concentration < 8.5 g/dL at Screening;

- Diagnosis of Down syndrome;

- History of malignancy within 5 years prior to screening, with the exception of
localized skin or cervical carcinomas;

- Untreated or uncontrolled active bacterial, fungal, or viral infection;

- Known or suspected active drug or alcohol abuse, per investigator judgment;

- Use of Herbalife supplements within 14 days prior to Day 1;

- Major surgery within 30 days prior to Day 1 or planned to occur during the course of
the study;

- Unwilling to practice acceptable methods of birth control (both males who have
partners of childbearing potential and females of childbearing potential) during
screening, while taking study drug, and for at least 30 days after the last dose of
study drug is ingested;

- Use of inhaled nitric oxide within 7 days prior to Screening and Day 1 visits,
excluding acute vasodilator testing during diagnostic cardiac catheterization;

- Women who are pregnant or breastfeeding;

- Any disability or impairment that would prohibit performance of the 6MWT;

- Any abnormal laboratory level that, in the opinion of the investigator, would put the
patient at risk by trial enrollment;

- Patient is, in the opinion of the investigator, unable to comply with the requirements
of the study protocol or is unsuitable for the study for any reason;

- Known hypersensitivity to any component of the study drug;

- Unable to communicate or cooperate with the investigator because of language problems,
poor mental development, or impaired cerebral function.
We found this trial at
41
sites
Washington, District of Columbia 20007
Principal Investigator: Tunay Kuru, MD
Phone: 202-444-6210
?
mi
from
Washington,
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
Principal Investigator: Flavia Castelino, MD
Phone: 617-726-7935
?
mi
from
Boston, MA
Click here to add this to my saved trials
72 East Concord Street
Boston, Massachusetts 02118
(617) 638-5300
Principal Investigator: Elizabeth Klings, MD
Phone: 617-638-4475
Boston University School of Medicine A leader in medical education and research, Boston University School...
?
mi
from
Boston, MA
Click here to add this to my saved trials
9500 Euclid Avenue
Cleveland, Ohio 44106
216.444.2200
Principal Investigator: Kristin Highland, MD
Phone: 216-444-2140
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Gainesville, Florida 32610
(352) 392-3261
Principal Investigator: Hassan Alnuaimat, MD
Phone: 352-273-8990
University of Florida The University of Florida (UF) is a major, public, comprehensive, land-grant, research...
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
7000 Fannin St
Houston, Texas 77030
(713) 500-4472
Principal Investigator: Namita Sood, MD
Phone: 713-500-6851
University of Texas Health Science Center at Houston The University of Texas Health Science Center...
?
mi
from
Houston, TX
Click here to add this to my saved trials
1601 Northwest 12th Avenue
Miami, Florida 33136
(305) 243-6545
Principal Investigator: Eric Greidinger, MD
Phone: 305-243-8567
University of Miami Miller School of Medicine The University of Miami Leonard M. Miller School...
?
mi
from
Miami, FL
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
503 494-8311
Principal Investigator: Akram Khan, MD
Phone: 503-494-9443
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
?
mi
from
Portland, OR
Click here to add this to my saved trials
201 Presidents Circle
Salt Lake City, Utah 84108
801) 581-7200
Principal Investigator: John Ryan, MD
Phone: 801-585-2944
University of Utah Research is a major component in the life of the U benefiting...
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
1000 W Carson St
Torrance, California 90502
Principal Investigator: Ronald J. Oudiz, MD
Phone: 310-222-2515
?
mi
from
Torrance, CA
Click here to add this to my saved trials
2950 Cleveland Clinic Blvd.
Weston, Florida 33331
866.293.7866
Principal Investigator: Franck Rahaghi, MD
Phone: 954-659-6213
Cleveland Clinic Florida Cleveland Clinic Florida, located in Weston, West Palm Beach, Palm Beach Gardens...
?
mi
from
Weston, FL
Click here to add this to my saved trials
Albuquerque, New Mexico 87131
(505) 277-0111
Principal Investigator: Lana Melendres, MD
Phone: 505-272-2273
University of New Mexico Founded in 1889 as New Mexico’s flagship institution, the University of...
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
500 S State St
Ann Arbor, Michigan 48109
(734) 764-1817
Principal Investigator: Vallerie McLaughlin, MD
Phone: 734-936-5383
University of Michigan The University of Michigan was founded in 1817 as one of the...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Augusta, Georgia 30912
Principal Investigator: James Gossage, MD
Phone: 706-721-6789
?
mi
from
Augusta, GA
Click here to add this to my saved trials
3820 Medical Park Dr
Austell, Georgia 30106
Principal Investigator: Chad Miller, MD
Phone: 770-745-1404
?
mi
from
Austell, GA
Click here to add this to my saved trials
Beverly Hills, California 90211
Principal Investigator: Antoine Hage, MD
Phone: 310-248-7134
?
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
843-792-1414
Principal Investigator: Rahul Argula, MD
Phone: 843-792-4349
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
?
mi
from
Charleston, SC
Click here to add this to my saved trials
Chicago, Illinois 60611
Principal Investigator: Michael Cuttica, MD
Phone: 312-695-2269
?
mi
from
Chicago, IL
Click here to add this to my saved trials
2035 W Taylor St
Chicago, Illinois
(312) 996-4350
Principal Investigator: Dustin Fraidenburg, MD
Phone: 312-355-5934
University of Illinois at Chicago A major research university in the heart of one of...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
2600 Clifton Ave
Cincinnati, Ohio 45267
(513) 556-6000
Principal Investigator: Jean Elwing, MD
Phone: 513-558-3077
University of Cincinnati The University of Cincinnati offers students a balance of educational excellence and...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Columbus, Ohio 43210
Principal Investigator: Veronica Franco, MD
Phone: 614-366-2258
?
mi
from
Columbus, OH
Click here to add this to my saved trials
1801 Inwood Rd
Dallas, Texas 75390
(214) 645-3300
Principal Investigator: Sonja Bartolome, MD
Phone: 214-645-6493
University of Texas Southwestern Medical Center UT Southwestern is an academic medical center, world-renowned for...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Principal Investigator: Ankoor Shah, MD
Phone: 919-684-6150
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Zeenat Safdar, MD
Phone: 713-363-7536
?
mi
from
Houston, TX
Click here to add this to my saved trials
3901 Rainbow Blvd
Kansas City, Kansas 66160
(913) 588-5000
Principal Investigator: Lewis Satterwhite, MD
Phone: 913-588-7117
University of Kansas Medical Center The University of Kansas Medical Center serves Kansas through excellence...
?
mi
from
Kansas City, KS
Click here to add this to my saved trials
9500 Gilman Dr
La Jolla, California 92093
(858) 534-2230
Principal Investigator: David Poch, MD
Phone: 858-657-7122
The University of California, San Diego UC San Diego is an academic powerhouse and economic...
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
10833 Le Conte Ave
Los Angeles, California 90095
(310) 825-4321
Principal Investigator: Rajan Saggar, MD
Phone: 310-794-3299
David Geffen School of Medicine, UCLA In 2002 Mr. David Geffen announced a $200 million...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Louisville, Kentucky 40202
Principal Investigator: John McConnell, MD
Phone: 502-587-8000
?
mi
from
Louisville, KY
Click here to add this to my saved trials
Milwaukee, Wisconsin 53215
Principal Investigator: Dianne Zwicke, MD
Phone: 414-649-5097
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
462 1st Avenue
New York, New York 10010
Principal Investigator: Roxana Sulica, MD
Phone: 212-844-8824
?
mi
from
New York, NY
Click here to add this to my saved trials
Norfolk, Virginia 23507
Principal Investigator: Michael Eggert, MD
Phone: 757-388-4024
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
3451 Walnut St
Philadelphia, Pennsylvania 19104
1 (215) 898-5000
Principal Investigator: Harold Palevsky, MD
Phone: 215-294-9759
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
1020 Walnut St
Philadelphia, Pennsylvania 19107
(215) 955-6000
Principal Investigator: Michael Scharf, MD
Phone: 215-955-8184
Thomas Jefferson University We are dedicated to the health sciences and committed to educating professionals,...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phoenix, Arizona 85013
Principal Investigator: Jeremy Feldman, MD
Phone: 602-271-0832
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Phoenix, Arizona 85004
Principal Investigator: Rajeev Saggar, MD
Phone: 602-839-0427
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Rochester, New York 14642
Principal Investigator: Jim White, MD
Phone: 585-486-0869
?
mi
from
Rochester, NY
Click here to add this to my saved trials
Sacramento, California 95817
Principal Investigator: Roblee Allen, MD
Phone: 916-734-1554
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Principal Investigator: Murali Chakinala, MD
Phone: 314-747-8174
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
San Diego, California 92103
Principal Investigator: David Riker, MD
Phone: 619-269-1652
?
mi
from
San Diego, CA
Click here to add this to my saved trials
Shreveport, Louisiana 71130
Principal Investigator: Samina Hayat, MD
Phone: 318-675-5592
?
mi
from
Shreveport, LA
Click here to add this to my saved trials
Spokane, Washington 99204
Principal Investigator: Richard Gower, MD
Phone: 509-496-2782
?
mi
from
Spokane, WA
Click here to add this to my saved trials